While the use of surrogate markers such as vimentin and synaptophysin can aid in glioma classification when molecular testing is unavailable, efforts should be made to improve global access to genetic testing technologies, ensuring that all patients receive accurate diagnoses and appropriate treatment recommendations. The gene discussed is SYP; the disease is central nervous system cancer.